hackettg

With the early May bank holiday (1 May 2023) occurring in the first five days of the submission window contractors have an extra day, until the end of 6th of May, to submit their April FP34C declaration using the Manage Your Service (MYS) portal and to dispatch their prescription bundle to the relevant pricing division at the [...]

The post Extended FP34C submission deadline for prescriptions dispensed in April 2023 appeared first on PSNC Website.

NHS Prescription Services produces a quarterly newsletter called “Hints & Tips for dispensing contractors”. The latest edition (Issue 51) contains some useful information and advice on: Patients claiming free NHS prescriptions Real Time Exemption Checking Submitting EPS tokens to the NHSBSA Submitting Accounts to Scanning Sites HRT PPC Disallowed Items New Medicine Service PPV To [...]

The post NHS Prescription Services ‘Hints & Tips’ – Issue 51 appeared first on PSNC Website.

The Department of Health and Social Care (DHSC) determined that from February 2023 onwards, Transitional Payments would be set to zero. This is reflected in the February Schedule of Payments received by contractors this month. In discussions with DHSC, PSNC had rejected the change to the Transitional Payments on the grounds that any further reductions [...]

The post Contractor reminder: Transitional Payments set to zero from February appeared first on PSNC Website.

The Drug Tariff Preface published monthly lists additions, deletions and other changes to products listed in the Drug Tariff. Below is a summary of the changes coming into effect from 1 May 2023. Key g Special container – This product is a special container and should be dispensed in its complete original pack size. n Item [...]

The post Drug Tariff Watch – May 2023 appeared first on PSNC Website.

Class 4 Medicines Defect Information: Co-amoxiclav 125/31.25mg/5ml, 250/62.5mg/5ml powder for oral suspension (Sandoz Limited) Drug alert number: EL (23)A/14 Date issued: 20 April 2023 The Medicines and Health products Regulatory Agency (MHRA) has issued a class 4 medicines defect information notice for: Product name: Co-amoxiclav 125/31.25mg/5ml powder for oral suspension, PL 04416/0514 (Sandoz Limited) SNOMED [...]

The post MHRA Class 4 Medicines Defect Information: Co-amoxiclav 125/31.25mg/5ml, 250/62.5mg/5ml powder for oral suspension (Sandoz Limited) appeared first on PSNC Website.